Introduction
============

Cervical cancer was the fourth leading cause of cancer death and the fourth most frequently diagnosed cancer among females worldwide in 2018 [@B1]. In China, 26,400 and 30,500 estimated deaths from cervical cancer were reported in 2013 and 2015, respectively [@B2], [@B3]. High-risk strains of human papillomavirus (HPV) are now well established as the causative agents responsible for invasive cervical cancer and its precursor, cervical intraepithelial neoplasia [@B4]. HPV infection is strongly associated with the risk of cervical cancer. Only a small number of women exhibit persistent infection with oncogenic HPV types that eventually lead to cervical cancer, and most HPV infections regress spontaneously [@B5]. Increasing evidence indicates that host genetic variations play critical roles in cervical carcinogenesis independent of HPV infection [@B6]-[@B9].

MicroRNAs (miRNAs) are a class of small regulatory RNAs that are processed from endogenous hairpin transcripts and function as regulators of gene expression in eukaryotes [@B10], [@B11]. In the nucleus, miRNAs are transcribed from genomic DNA into long primary transcripts (pri-miRNAs) and can be cleaved into 60-70-nucleotide precursor miRNAs (pre-miRNAs) by nuclear Drosha [@B12], [@B13]. Next, the pre-miRNAs are further processed into mature miRNAs of approximately 21-25 nucleotides in length [@B14], [@B15]. Polymorphisms or mutations in the promoter or the miRNA sequence itself may result in changes in the structure or expression of miRNAs, which affect the expression of hundreds of target genes. Cancer susceptibility and prognosis cancer may be affected by polymorphisms in miRNAs [@B16]. Recent studies have shown that the genetic variants in pre-miRNAs are associated with the risks and clinical outcomes of many types of cancers [@B17]-[@B20], including cervical cancer [@B7], [@B21]. In this study, we sought to identify common genetic polymorphisms of pre-miRNAs associated with the risk of cervical cancer susceptibility in southern Chinese women.

Materials and Methods
=====================

Patients and controls
---------------------

In the present case-control study, 290 cervical cancer patients (mean ± standard deviation (SD), 50.10 ± 10.51) were enrolled at the Second Affiliated Hospital and Yuying Children\'s Hospital of Wenzhou Medical University (WMU) from February 2007 to February 2017. The diagnosis of cervical cancer was confirmed in all cases by histological examination of tissues from biopsies or resected specimens. Cancer-free controls (n=535, mean ± SD, 57.84 ± 15.47) were recruited from the same hospital during routine physical examinations, and we excluded participants who had been diagnosed with malignant neoplasm or a family history of cancers. This study was approved by the Second Affiliated Hospital and Yuying Children\'s Hospital of WMU (Ethics Reference No: LCKY2019-274), and written informed consent was obtained from all patients.

Polymorphism selection and genotyping
-------------------------------------

Eight widely investigated polymorphisms (*pre-miR-137* rs1625579 T\>G, *pre-miR-27a* rs895819 T\>C, *pre-miR-146a* rs2910164 C \> G, *pre-miR-149* rs2292832 T\>C, *pre-miR-196a2* rs11614913 T\>C, *pre-miR-218* rs11134527 A\>G, *pre-miR-423* rs6505162 C\>A, and *pre-miR-608* rs4919510 G\>C) were selected [@B17]. The minor allele frequency of all eight polymorphisms was greater than 0.05. Seven of the polymorphisms were located in transcription factor binding sites, as predicted by SNPinfo (<https://snpinfo.niehs.nih.gov/>), and the rs1625579 polymorphism is located in an intron of the *miR-137* gene, which is significantly associated with schizophrenia risk [@B22].

The TIAN quick FFPE DNA Kit (Qiagen NV, Venlo, the Netherlands) was applied to extract genomic DNA from all patients from paraffin-embedded tissues, while genomic DNA from the controls was extracted from peripheral blood specimens using the TIANamp Blood DNA Kit (TianGenBiotech, Beijing, China) as we described previously [@B23], [@B24]. A UV absorption spectrophotometer was used to detect DNA purity and concentrations.

Genotyping analysis was performed by real-time PCR with TaqMan PCR master mix and the ABI Prism 7900HT genetic detection system. The details of the analysis procedures have been previously described [@B25]. In addition, approximately 5% of the samples were randomly selected as positive and negative controls for assessing the accuracy of genotyping results.

Statistical analysis
--------------------

The goodness-of-fit chi-square test was adopted to evaluate departure from Hardy-Weinberg equilibrium (HWE) for the selected polymorphisms in control subjects. The heterogeneity of the genotypes and ages between patients and controls was evaluated by using a 2-sided chi-square test. The association between pre-miRNA polymorphisms and cervical cancer risk was assessed with an unconditional logistic regression model, calculated as the crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Additionally, stratified analyses were performed by age, menopause, the number of vaginal pregnancies, the number of abortions, clinical stages and pathological stages. All statistical tests were carried out by using SAS software (Version 9.4; SAS Institute, Cary, NC, USA), with a two-sided *P*-value \< 0.05 considering significant controls.

Results
=======

Characteristics of the study participants
-----------------------------------------

In the present study, we enrolled 290 cervical cancer patients and 445 cancer-free controls. The frequency distributions of the selected demographic characteristics of the cases and controls are shown in Table [1](#T1){ref-type="table"}. The incidence of abortion in the patients (43.5%) was much higher than that in the control subjects (4.9%), implying that a high incidence of abortion was a critical risk factor for cervical cancer development in our study population. In addition, compared with the controls, the distribution of age in the cervical cancer cases was much younger. Among the 290 cases, 105 (36.2%) were postmenopausal women. However, there was no significant difference in the number of vaginal deliveries between the cases and controls. There were 208 patients (71.7%) who had squamous cell carcinomas; other patients who had adenocarcinoma or adenosquamous carcinoma or were unclassified were represented 28.3% of the study population. Among all 290 cases, 70.0% of patients were classified as stage I and 21.0%, 1.7%, and 0.7% as stages II, III, and IV, respectively, while 6.6% of the patients were classified as being in other stages (Table [1](#T1){ref-type="table"}).

Association between selected pre-miRNA polymorphisms and cervical cancer risk
-----------------------------------------------------------------------------

To investigate the association with cervical cancer risk of each of the eight selected pre-miRNA polymorphisms, the HWE test was first used to identify genotyping errors in the cancer-free controls. As shown in Table [2](#T2){ref-type="table"}, most of the genotype distributions were in accordance with HWE (*P* values ranged from 0.215 to 0.953), except that the pre-miR-149 rs2292832 T \> C and pre-miR-218 rs11134527 A \> G polymorphisms exhibited significant deviation from HWE in the controls (*P*\<0.001). Next, through allelic association analysis, we found that the pre-miR-137 rs1625579 T \> G polymorphism was significantly associated with decreased cervical cancer risk (TG/GG versus TT: adjusted odds ratio (AOR) = 0.47, 95% CI = 0.27-0.81, *P*=0.007; TG versus TT: AOR = 0.56, 95% CI = 0.34-0.91, *P*=0.018). The pre-miR-27a rs895819 T \> C polymorphism was also shown to significantly decrease cervical cancer susceptibility (TC/CC versus TT: AOR = 0.65, 95% CI = 0.44-0.96, *P*=0.030). These findings suggest that these two polymorphisms may be common pre-miRNA polymorphisms that influence the risk of cervical cancer susceptibility in southern Chinese women.

Stratified analysis
-------------------

We further explored the association of the pre-miR-137 rs1625579 T \> G and pre-miR-27a rs895819 T \> C polymorphisms with cervical cancer susceptibility through stratified analysis. We found that the protective effects of the pre-miR-137 rs1625579 T \> G and pre-miR-27a rs895819 T \> C polymorphisms were significant in patients younger than 49 years, those exhibiting fewer abortions, and those in clinical stage I (Table [3](#T3){ref-type="table"}). Moreover, the protective effect of the *pre-miR-137* rs1625579 T \> G polymorphism was also observed in premenopausal women, patients with squamous cell carcinoma, and patients with unclassified types of pathologies, while the *pre-miR-27a* rs895819 T \> C polymorphism was also associated a low risk of cervical cancer susceptibility in patients older than 49 years, those who were menopausal, and those who had experienced vaginal pregnancies (Table [3](#T3){ref-type="table"}).

Discussion
==========

In the current case-control study, we explored the associations of eight common polymorphisms in pre-miRNAs with cervical cancer susceptibility in southern Chinese women. We found that the *pre-miR-137* rs1625579 T\>G and *pre-miR-27a* rs895819 T \> C polymorphisms were significantly associated with decreased cervical cancer risk. Our findings suggest that the *pre-miR-137* rs1625579 T\>G and *pre-miR-27a* rs895819 T \> C polymorphisms may play critical roles in the aetiology of cervical cancer.

Tumour-suppressive functions of miR-137 in cervical cancer have been recently reported [@B26]. Endogenous miR-137 expression is downregulated in both cervical cancer cell lines and tissues, and overexpression of miR-137 in cervical cancer cells substantially inhibits cell proliferation, migration and transplantation in nude mice [@B26]. In our study, the results showed that the *pre-miR-137* rs1625579 T\>G polymorphism exhibits a protective effect against cervical cancer, suggesting that the *pre-miR-137* rs1625579 T\>G polymorphism may present a positive correlation with miR-137 expression. Further studies are needed to confirm this hypothesis.

Remarkably, we also found that the *pre-miR-27a* rs895819 T\>C polymorphism exerted a protective effect on cervical cancer risk. This finding is consistent with a previous study conducted in cervical cancer [@B7]. It is worth noting that our results demonstrated that the *pre-miR-27a* rs895819 T\>C polymorphism exerted a protective effect against cervical cancer risk in dominant genetic model, while Xiong et al. found that the *pre-miR-27a* rs895819 T\>C polymorphism played a protective role in a recessive genetic model but found no associations in other genetic models [@B7]. Although the participants of Xiong et al.\' study and our study were both selected from among southern Chinese women, the sample size in the current study was larger than the sample size in the Xiong et al. study (including 103 cervical cancer patients and 417 cancer-free controls). Thus, the differences may result from the baseline characteristics and the larger number of samples.

Additionally, previous studies have suggested that the *pre-miR-149* rs2292832 T \> C polymorphism is associated with an increased risk of cervical cancer susceptibility [@B27] and that the *pre-miR-218* rs11134527 A \> G polymorphism is associated with a decreased risk of cervical cancer susceptibility [@B28], [@B29]. However, our study did not identify a significant association of these two polymorphisms with cervical cancer risk. This inconsistency with previous studies may be due to the genotype distributions of the *pre-miR-149* rs2292832 T \> C and *pre-miR-218* rs11134527 A \> G polymorphisms significantly deviating from HWE in the controls. For the other pre-miRNA polymorphisms, no associations were found with the risk of cervical cancer susceptibility in the current study, so further studies are required for confirmation.

Although the current case-control study provides evidence that common pre-miRNA polymorphisms are associated with the risk of cervical cancer susceptibility in southern Chinese women, several limitations should be addressed. First, only eight common pre-miRNA polymorphisms were genotyped in the current study; hence, more common pre-miRNA polymorphisms should be investigated to fully illuminate the contribution of polymorphisms in pre-miRNAs to cervical cancer susceptibility. Second, the sample size in the current study was relatively small. Additionally, the selected samples came from a single hospital in the current hospital-based case-control study, which may result in selection bias or even a decreased or increased risk assessment. Third, in addition to polymorphisms, many that confounders may also influence susceptibility to cervical cancer, such as gene-gene interactions, gene-environment interactions, and the specific tumour pathologic classification, were not taken into consideration due to the lack of individual information. Fourth, although our findings suggested that the *pre-miR-137* rs1625579 T \> G and *pre-miR-27a* rs895819 T \> C polymorphisms show a statistically significant association with the risk of cervical cancer, much more research is needed to confirm this result and to detect the potential related mechanisms and functions in the future.
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miRNAs

:   microRNAs

pre-miRNAs
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###### 

Frequency distribution of selected variables in cervical cancer cases and cancer-free controls

  Characteristic            Cases (n=290)   Controls (n=445)   *P^a^*
  ------------------------- --------------- ------------------ ----------
  **Age**                                                      
  Mean ± SD                 50.10 ± 10.51   57.84 ± 15.47      
  ≤49                       150 (51.7%)     118 (26.5%)        \<0.0001
  \>49                      140 (48.28%)    327 (73.5%)        
  **Menopause**                                                
  No                        185 (63.8%)     131 (29.4%)        \<0.0001
  Yes                       105 (36.2%)     314 (70.6%)        
  **Delivery**                                                 
  No                        2 (0.71%)       10 (2.30%)         0.107
  Yes                       279 (99.3%)     425 (97.7%)        
  **Abortion**                                                 
  No                        164 (56.6%)     423 (95.1%)        \<0.0001
  Yes                       126 (43.5%)     22 (4.9%)          
  **Pathology**                                                
  Squamous cell carcinoma   208 (71.7%)                        
  Adenocarcinoma            44 (15.2%)                         
  Adenosquamous carcinoma   3 (1.0%)                           
  Other                     35 (12.1%)                         
  **FIGO stages**                                              
  I                         203 (70.0%)                        
  II                        61 (21.0%)                         
  III                       5 (1.7%)                           
  IV                        2 (0.7%)                           
  Others                    19 (6.6%)                          

**^a^**Two-sided χ^2^ test for the distribution between cervical cancer cases and cancer-free controls.

###### 

Association between selected polymorphisms and cervical cancer determined by logistic regression analyses

  miRNA         SNP          Allele   Case (N=290)   Control (N=445)   Dominant   Recessive         Heterozygous        HWE                                                                              
  ------------- ------------ -------- -------------- ----------------- ---------- ----------- ----- -------------- ---- ------------------ ------- ------------------ ------- ------------------ ------- ---------
  *miR-137*     rs1625579    T        G              254               26         7           361   75             5    0.47 (0.27-0.81)   0.007   1.19 (0.23-6.25)   0.834   0.56 (0.34-0.91)   0.018   0.621
  *miR-27a*     rs895819     T        C              202               76         11          252   158            31   0.65 (0.44-0.96)   0.030   1.01 (0.46-2.23)   0.980   0.75 (0.55-1.04)   0.083   0.365
  *miR-146a*    rs2910164    C        G              118               123        49          152   209            80   0.74 (0.51-1.09)   0.129   0.84 (0.52-1.36)   0.479   0.83 (0.64-1.08)   0.162   0.582
  *miR-149*     rs2292832    T        C              185               57         28          309   76             42   1.07 (0.71-1.64)   0.741   0.94 (0.50-1.79)   0.859   1.02 (0.77-1.36)   0.885   \<0.001
  *miR-196a2*   rs11614913   T        C              105               125        58          140   220            80   0.72 (0.49-1.07)   0.100   1.26 (0.79-2.00)   0.330   0.93 (0.72-1.21)   0.585   0.691
  *miR-218*     rs11134527   A        G              93                123        61          185   160            85   1.16 (0.79-1.71)   0.460   1.22 (0.77-1.95)   0.400   1.13 (0.88-1.45)   0.350   \<0.001
  *miR-423*     rs6505162    C        A              180               89         11          291   120            18   1.48 (1.01-2.19)   0.057   1.86 (0.81-4.24)   0.142   1.43 (1.04-1.96)   0.029   0.215
  *miR-608*     rs4919510    G        C              108               129        51          125   219            97   0.74 (0.50-1.11)   0.144   1.02 (0.65-1.61)   0.928   0.89 (0.69-1.15)   0.372   0.953

OR, odds ratio; CI, confidence interval. HWE, Hardy-Weinberg equilibrium. Heterozygous (AB versus AA), dominant (AB/BB versus AA), recessive (BB versus AB/AA). ^a^Adjusted for age, menopause, number of vaginal pregnancies, abortion, clinical stages and pathology.

###### 

Stratification analysis for the associations of the rs895819 T \> C and rs1625579 T \> G polymorphisms with cervical cancer risk

  Variables                 *miR-137* rs1625579 (cases/controls)   AOR (95% CI)   *P*^a^               *miR-27a* rs895819 (cases/controls)   AOR (95% CI)   *P*^a^                      
  ------------------------- -------------------------------------- -------------- -------------------- ------------------------------------- -------------- -------- ------------------ -------
  **Age (years)**                                                                                                                                                                       
  ≤49                       133/89                                 15/28          0.36 (0.18-0.71)     0.003                                 106/68         44/50    0.57 (0.34-0.94)   0.027
  \>49                      121/272                                18/52          0.78 (0.44-1.39)     0.394                                 196/184        43/139   0.59 (0.39-0.90)   0.015
  **Menopause**                                                                                                                                                                         
  No                        161/99                                 22/31          0.44 (0.24-0.80)     0.007                                 124/78         60/53    0.71 (0.45-1.13)   0.153
  Yes                       93/262                                 11/49          0.63 (0.32-1.27)     0.197                                 78/174         27/136   0.44 (0.27-0.72)   0.001
  **Delivery**                                                                                                                                                                          
  No                        1/9                                    1/1            9.00 (0.28-285.45)   0.213                                 2/7            0/3      \-                 0.962
  Yes                       245/346                                31/75          0.58 (0.37-0.92)     0.019                                 195/242        83/179   0.58 (0.42-0.79)   0.008
  **Abortion**                                                                                                                                                                          
  No                        146/350                                16/78          0.49 (0.28-0.87)     0.015                                 110/243        54/185   0.65 (0.44-0.94)   0.023
  Yes                       108/11                                 17/2           0.87 (0.18-4.25)     0.859                                 92/9           33/4     0.81 (0.23-2.80)   0.735
  **Clinical stage**                                                                                                                                                                    
  I                         177/361                                24/80          0.45 (0.24-0.82)     0.010                                 142/252        60/189   0.64 (0.42-0.98)   0.041
  II                        53/361                                 7/80           0.55 (0.23-1.34)     0.190                                 44/252         17/189   0.61 (0.32-1.16)   0.133
  III                       4/361                                  1/80           1.47 (0.14-15.34)    0.746                                 3/252          2/189    1.19 (0.16-8.68)   0.868
  IV                        2/361                                  0/80           \-                   \-                                    1/252          1/189    \-                 \-
  Others                    18/361                                 1/80           0.29 (0.04-2.34)     0.246                                 12/252         7/189    0.48 (0.14-1.63)   0.241
  **Pathology**                                                                                                                                                                         
  Squamous cell carcinoma   180/361                                25/80          0.51 (0.29-0.92)     0.024                                 143/252        64/189   0.68 (0.45-1.02)   0.065
  Adenocarcinoma            38/361                                 6/80           0.65 (0.24-1.72)     0.380                                 32/252         12/189   0.52 (0.24-1.14)   0.102
  Adenosquamous carcinoma   3/361                                  0/80           \-                   \-                                    2/252          1/189    \-                 \-
  Others                    33/361                                 2/80           0.16 (0.03-0.87)     0.034                                 25/252         10/189   0.54 (0.22-1.32)   0.177

AOR, adjusted odds ratio; CI, confidence interval. ^a^ Obtained in logistic regression models with adjustment for age, menopause, delivery, and abortion.
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